×
About 20,230 results

ALLMedicine™ Parkinson Disease Center

Research & Reviews  9,671 results

Advances and Future Directions of Neuromodulation in Neurologic Disorders.
https://doi.org/10.1016/j.ncl.2020.09.004
Neurologic Clinics; Burns MR, Chiu SY et. al.

Nov 23rd, 2020 - "Deep brain stimulation is a safe and effective therapy for the management of a variety of neurologic conditions with Food and Drug Administration or humanitarian exception approval for Parkinson disease, dystonia, tremor, and obsessive-compulsive...

Investigation of Sensorimotor Dysfunction in Parkinson Disease by Resting-state fMRI.
https://doi.org/10.1016/j.neulet.2020.135512
Neuroscience Letters; Wang S, Zhang Y et. al.

Nov 22nd, 2020 - Functional MRI has played a fundamental role in Parkinson's disease(PD) study. In this paper, we performed an independent component analysis (ICA) based on functional networks to reveal the intricate variations on the morphology and functional pro...

Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678051
Acta Neuropathologica Communications; Ibanez L, Bahena JA et. al.

Nov 20th, 2020 - Alpha-synuclein is the main protein component of Lewy bodies, the pathological hallmark of Parkinson's disease. However, genetic modifiers of cerebrospinal fluid (CSF) alpha-synuclein levels remain unknown. The use of CSF levels of amyloid beta1-4...

Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668461
Medicine Popa LC, Leucuta DC et. al.

Nov 12th, 2020 - Levodopa-carbidopa intestinal gel (LCIG) is a method of continuous administration of levodopa - the standard treatment in Parkinson disease (PD, a neurodegenerative disorder characterized by resting tremor, rigidity, gait impairment, and bradykine...

Ring Finger Protein 11 (RNF11) Modulates Dopamine Release in Drosophila.
https://doi.org/10.1016/j.neuroscience.2020.10.021
Neuroscience Privman Champaloux E, Donelson N et. al.

Nov 11th, 2020 - Recent work indicates a role for RING finger protein 11 (RNF11) in Parkinson disease (PD) pathology, which involves the loss of dopaminergic neurons. However, the role of RNF11 in regulating dopamine neurotransmission has not been studied. In this...

see more →

Guidelines  155 results

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon ...

Canadian guideline for Parkinson disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733687
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne; Grimes D, Fitzpatrick M et. al.

Sep 10th, 2019 - Canadian guideline for Parkinson disease.|2019|Grimes D,Fitzpatrick M,Gordon J,Miyasaki J,Fon EA,|methods,therapeutic use,methods,diagnosis,physiopathology,therapy,

see more →

Drugs  15 results see all →

Clinicaltrials.gov  9,917 results

Advances and Future Directions of Neuromodulation in Neurologic Disorders.
https://doi.org/10.1016/j.ncl.2020.09.004
Neurologic Clinics; Burns MR, Chiu SY et. al.

Nov 23rd, 2020 - "Deep brain stimulation is a safe and effective therapy for the management of a variety of neurologic conditions with Food and Drug Administration or humanitarian exception approval for Parkinson disease, dystonia, tremor, and obsessive-compulsive...

Investigation of Sensorimotor Dysfunction in Parkinson Disease by Resting-state fMRI.
https://doi.org/10.1016/j.neulet.2020.135512
Neuroscience Letters; Wang S, Zhang Y et. al.

Nov 22nd, 2020 - Functional MRI has played a fundamental role in Parkinson's disease(PD) study. In this paper, we performed an independent component analysis (ICA) based on functional networks to reveal the intricate variations on the morphology and functional pro...

Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678051
Acta Neuropathologica Communications; Ibanez L, Bahena JA et. al.

Nov 20th, 2020 - Alpha-synuclein is the main protein component of Lewy bodies, the pathological hallmark of Parkinson's disease. However, genetic modifiers of cerebrospinal fluid (CSF) alpha-synuclein levels remain unknown. The use of CSF levels of amyloid beta1-4...

Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668461
Medicine Popa LC, Leucuta DC et. al.

Nov 12th, 2020 - Levodopa-carbidopa intestinal gel (LCIG) is a method of continuous administration of levodopa - the standard treatment in Parkinson disease (PD, a neurodegenerative disorder characterized by resting tremor, rigidity, gait impairment, and bradykine...

Ring Finger Protein 11 (RNF11) Modulates Dopamine Release in Drosophila.
https://doi.org/10.1016/j.neuroscience.2020.10.021
Neuroscience Privman Champaloux E, Donelson N et. al.

Nov 11th, 2020 - Recent work indicates a role for RING finger protein 11 (RNF11) in Parkinson disease (PD) pathology, which involves the loss of dopaminergic neurons. However, the role of RNF11 in regulating dopamine neurotransmission has not been studied. In this...

see more →

News  459 results

A Breakthrough in Parkinson Disease and New Data on Treating Stroke
https://www.medscape.com/viewarticle/933212

Jul 12th, 2020 - This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany, presenting six very interesting publications from February 2020 in the fields of stroke, multiple s...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.staging.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

see more →

Patient Education  13 results see all →